iBio, Inc.
IBIO evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $59.9M
- Lead Asset:
- ibio-600 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for IBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IBIO
iBio, Inc. is a preclinical-stage biotechnology company applying an AI-driven antibody discovery platform to develop therapeutics for obesity, cardiometabolic disease, and immune-oncology, with its lead candidate IBIO-610 targeting Activin E and its first clinical trial expected in early 2027.
Key risk: No clinical-stage assets
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$59.9M
Cash Runway
—
Lead Asset
ibio-600 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for iBio, Inc..
iBio, Inc. is a preclinical-stage biotechnology company applying an AI-driven antibody discovery platform to develop therapeutics for obesity, cardiometabolic disease, and immune-oncology, with its lead candidate IBIO-610 targeting Activin E and its first clinical trial expected in early 2027.
- iBio's current therapeutics are all in preclinical development and the company has not completed any clinical trials in humans for any therapeutic protein product candidate [sec · filed 2025-11-17].
- The company anticipates the commencement of its first human clinical trials for IBIO-610 in early 2027 [sec · filed 2025-11-17].
- iBio reported cash & equivalents of $56.4M and shareholders' equity of $85.7M as of 2026-06-30 [sec].
- The company raised gross proceeds of approximately $50 million from an underwritten public offering in August 2025 and approximately $26 million from a private placement in January 2026 [sec_mda · as of 2026-05-12].
- iBio's AI Drug Discovery Platform integrates generative AI tools with mammalian display technology to progress from concept to development-ready antibody in as little as seven months [sec · filed 2025-11-17].
What works
- iBio's AI Drug Discovery Platform enables rapid iteration between in silico design and wet-lab validation, compressing the timeline from hypothesis to lead selection [sec · filed 2025-11-17].
- The company has a focused preclinical pipeline targeting obesity and cardiometabolic disease, with a strategy to develop therapies that complement or follow GLP-1 treatment or provide well-tolerated monotherapy alternatives [sec · filed 2025-11-17].
- iBio has raised significant capital through public and private offerings, with cash & equivalents of $56.4M as of 2026-06-30, providing a runway to fund operations for at least 12 months from September 2025 [sec · filed 2025-11-17][sec].
What to weigh
- iBio has not generated any material revenue from its platform or pipeline and does not expect revenue for many years, if at all [sec · filed 2025-11-17].
- The company has a history of significant losses and negative cash flow from operations, raising substantial doubt about its ability to continue as a going concern [sec · filed 2025-11-17].
- All of iBio's therapeutic candidates are in preclinical development, and there is a risk the company will be unsuccessful in developing or commercializing any product candidates [sec · filed 2025-11-17].
- The company's ability to generate future revenue is dependent on successful development, regulatory approval, and commercialization, which are subject to significant risks and uncertainties including clinical trial outcomes and FDA review timelines [sec · filed 2025-11-17].
From the filings
Quoted directly from source documents.
iBio's therapeutics are all in preclinical development and no human clinical trials have been completed.
“Our current therapeutics are all in preclinical development and we have not completed any clinical trials in humans for any therapeutic protein product candidate produced using our technology”
SEC filings · November 17, 2025
iBio anticipates first human clinical trials for IBIO-610 in early 2027.
“we anticipate the commencement of our first human clinical trials in early 2027”
SEC filings · November 17, 2025
iBio's AI platform can progress from concept to development-ready antibody in as little as seven months.
“we can progress from concept to development-ready antibody in as little as seven months”
SEC filings · November 17, 2025
iBio has raised substantial capital but has a history of significant losses and negative cash flow.
“the history of significant losses, the negative cash flow from operations, and the dependence by us on our ability to obtain additional financing to fund our operations raised substantial doubt about our ability to continue as a going concern”
SEC filings · November 17, 2025
Risks & what to watch (4)›
Key risks
- No clinical-stage assets — All therapeutic candidates are preclinical; no human trials completed, risking development failure [sec · filed 2025-11-17].
- No revenue generation — Platform has not generated material revenue; no revenue expected for years, if at all [sec · filed 2025-11-17].
- Going concern doubts — History of significant losses and negative cash flow raises substantial doubt about viability [sec · filed 2025-11-17].
- Dependence on financing — Company relies on additional financing to fund operations; future funding not assured [sec · filed 2025-11-17].
What to watch
- Initiation of Phase 1 clinical trials for IBIO-610, expected in early 2027 [sec · filed 2025-11-17].
- Progress of IBIO-600 toward Phase 1a clinical trials, anticipated in the first half of calendar 2026 [sec_mda · as of 2026-02-10].
- Cash runway and ability to secure additional financing beyond the current $56.4M cash position [sec].
- Any partnerships or collaborations leveraging the AI Drug Discovery Platform for future revenue [sec · filed 2025-11-17].
Sources: SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run iBio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available iBio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.16
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 9.5%
- Days to cover
- 4.3
- Shares short
- 3,416,605
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for iBio, Inc.?
iBio, Inc. is a preclinical-stage biotechnology company applying an AI-driven antibody discovery platform to develop therapeutics for obesity, cardiometabolic disease, and immune-oncology, with its lead candidate IBIO-610 targeting Activin E and its first clinical trial expected in early 2027.
What is iBio, Inc.'s lead drug candidate?
iBio, Inc.'s most advanced tracked candidate is ibio-600 (Phase 1) for Overweight , Obesity.
Who is the CEO of iBio, Inc.?
Dr. Martin B. Brenner D.V.M., Ph.D. is the chief executive officer of iBio, Inc. (IBIO).
Where is iBio, Inc. headquartered?
iBio, Inc. (IBIO) is headquartered in San Diego, CA, United States.
What therapeutic areas does iBio, Inc. focus on?
iBio, Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.